Black Rock Inc. Orgenesis Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Orgenesis Inc. stock. As of the latest transaction made, Black Rock Inc. holds 79,889 shares of ORGS stock, worth $95,866. This represents 0.0% of its overall portfolio holdings.

Number of Shares

79,889

Previous 125,225 36.2%

Holding current value

$95,866

Previous $102,000 53.92%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.39 - $0.63 $17,681 - $28,561	-45,336 Reduced 36.2%	79,889 $47,000
Q1 2024 May 10, 2024	SELL	$0.28 - $0.9 $709 - $2,280	-2,534 Reduced 1.98%	125,225 $102,000
Q4 2023 Feb 13, 2024	BUY	$0.44 - $0.96 $4,389 - $9,576	9,975 Added 8.47%	127,759 $63,000
Q3 2023 Nov 13, 2023	SELL	$0.41 - $1.4 $6,063 - $20,703	-14,788 Reduced 11.15%	117,784 $73,000
Q2 2023 Aug 11, 2023	BUY	$1.01 - $1.44 $10,646 - $15,179	10,541 Added 8.64%	132,572 $184,000
Q1 2023 May 12, 2023	BUY	$1.18 - $2.59 $1,733 - $3,804	1,469 Added 1.22%	122,031 $143,000
Q4 2022 Feb 13, 2023	BUY	$1.18 - $2.24 $138 - $262	117 Added 0.1%	120,562 $235,000
Q3 2022 Nov 14, 2022	SELL	$1.38 - $2.38 $2,252 - $3,884	-1,632 Reduced 1.34%	120,445 $171,000
Q2 2022 Aug 12, 2022	SELL	$1.8 - $3.74 $10,161 - $21,112	-5,645 Reduced 4.42%	122,077 $295,000
Q1 2022 May 12, 2022	SELL	$2.31 - $3.72 $5,966 - $9,608	-2,583 Reduced 1.98%	127,722 $444,000
Q4 2021 Feb 10, 2022	BUY	$2.61 - $4.9 $8,177 - $15,351	3,133 Added 2.46%	130,305 $376,000
Q3 2021 Nov 09, 2021	SELL	$4.6 - $5.44 $4,089 - $4,836	-889 Reduced 0.69%	127,172 $631,000
Q2 2021 Aug 11, 2021	BUY	$4.19 - $5.88 $536,575 - $752,998	128,061 New	128,061 $650,000

Others Institutions Holding ORGS

# of Institutions

Shares Held

1.54M

Call Options Held

Put Options Held

View Full List

About Orgenesis Inc.

Ticker ORGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,545,800
Market Cap $30.7M
Description
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, ...

More about ORGS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account